What Is Epithalon?
Epithalon (Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide Epithalamin — most studied for telomerase activation, circadian rhythm regulation, and longevity research.
Epithalon (also spelled Epitalon, and sometimes referred to as Epitalone or by its sequence designation AEDG) is a synthetic tetrapeptide comprising the amino acid sequence Ala-Glu-Asp-Gly. It was developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, where it has been the subject of research spanning more than four decades. Epithalon is a synthetic analog of Epithalamin — a polypeptide complex naturally produced by the pineal gland — designed to isolate and replicate the bioregulatory activity of the native pineal extract in a chemically defined, reproducible form.
The molecular formula of Epithalon is C14H22N4O9, with a molecular weight of 390.35 Da. Its small tetrapeptide structure gives it favourable aqueous solubility and relatively high stability compared to larger peptide sequences, making it a tractable research compound for cell-based assays. In laboratory settings, Epithalon is primarily studied for its effects on telomerase expression, telomere maintenance, circadian rhythm regulation via melatonin modulation, and age-related changes in oxidative stress markers.
The compound's primary research significance lies in a series of in vitro and animal model studies, most prominently from Khavinson's group, demonstrating its ability to activate telomerase in somatic cells that normally exhibit negligible telomerase activity. These findings — if replicated and extended through rigorous clinical investigation — would have substantial implications for cellular ageing biology. However, as of 2026, no large-scale randomised controlled trials in humans have been published, and all Epithalon supplied by Rainbow Peptide is strictly For Research Use Only. It is not a drug, supplement, or approved therapeutic product of any kind.
Mechanism of Action
Epithalon activates telomerase (hTERT) to extend telomere length, restores melatonin secretion via pineal gland regulation, and modulates chromatin structure to reactivate silenced longevity genes — making it a multi-target anti-aging research compound.
- ◆
Telomerase Activation in Somatic Cells The most studied mechanism involves Epithalon's apparent ability to activate the enzyme telomerase (hTERT, human Telomerase Reverse Transcriptase) in somatic cells — cells that normally downregulate telomerase expression after development. Khavinson et al. (2003, Bulletin of Experimental Biology and Medicine) demonstrated that Epithalon-treated human fetal fibroblasts maintained telomere length across 44 population doublings — significantly longer than untreated controls — and expressed measurable telomerase activity confirmed by TRAP assay. The upstream signalling pathway mediating this activation has not been fully characterised.
- ◆
Melatonin Synthesis Modulation As a pineal gland-derived peptide analog, Epithalon research has investigated its interaction with pineal gland function. Animal model studies suggest Epithalon may stimulate melatonin production in aged subjects whose pineal function has declined. Melatonin's role as an antioxidant and circadian rhythm regulator is well-established; the downstream effects of restoring melatonin synthesis in research models include improvements in oxidative stress markers and circadian rhythm parameters. This mechanism is studied as a parallel, potentially independent pathway from the telomere effects.
- ◆
Chromatin Remodelling & Gene Expression Research by Khavinson and Vanyushin (2010) proposed that AEDG tetrapeptides including Epithalon interact with histone proteins and alter chromatin condensation state. This epigenetic mechanism was hypothesised to explain the broad range of gene expression changes observed in Epithalon-treated cell cultures and animal models. The proposed interaction with H1 histone and its effect on DNA accessibility suggests Epithalon may function as a chromatin-level bioregulator — a class of peptides described extensively in the Russian biogerontology literature.
- ◆
Antioxidant Activity & Reactive Oxygen Species Multiple in vitro studies have reported that Epithalon reduces lipid peroxidation markers and superoxide dismutase activity in aged cell models and rodent tissues. The antioxidant effect is not attributed to direct radical scavenging (the peptide has no obvious chemical antioxidant moiety) but rather to upregulation of endogenous antioxidant enzyme systems. This is a secondary mechanism that may contribute to the cellular longevity effects observed in model systems.
Key Research Findings
| Study | Model | Duration | Key Finding |
| Khavinson et al. (2003), Bull Exp Biol Med | Human fetal fibroblasts (WI-38) | 44 population doublings | Telomere length maintained 12% longer than controls; telomerase activity confirmed by TRAP assay; hayflick limit extended by ~10 passages |
| Kossoy et al. (2009), Int J Oncol | HER2/neu transgenic female mice | Lifetime | Spontaneous mammary tumour incidence reduced from 73% (control) to 28% (Epithalon-treated); mean tumour size significantly reduced; survival increased |
| Anisimov et al. (2003), Mech Ageing Dev | Aged male rats (Wistar) | 12 months | Melatonin levels restored to near-youth baseline; lipid peroxide levels reduced 22% vs. controls; physical activity markers maintained through month 12 vs. age-related decline in controls |
| Khavinson & Morozov (2003), Ann NY Acad Sci | Drosophila melanogaster model | Lifespan study | Mean lifespan extended 11–16% in Epithalon-treated groups; maximum lifespan increased; age-related locomotor decline delayed by approximately 2 weeks relative to control |
| Kozina et al. (2007), Bull Exp Biol Med | Aged rat brain tissue (cortex) | 21 days | SOD activity increased 34% vs. controls; glutathione peroxidase levels elevated; malondialdehyde (lipid peroxidation marker) reduced 28%; mitochondrial membrane potential improved |
Most Epithalon research originates from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. Independent replication in Western research institutions remains limited as of 2026. All findings are from laboratory and animal model research. No Phase 3 human RCT data is available.
Epithalon & Telomere Biology: Research Context
To understand Epithalon's proposed mechanism, a brief overview of telomere biology is necessary. Telomeres are repetitive DNA sequences (TTAGGG in humans) capping chromosome ends, serving as protective caps that prevent chromosomal degradation and end-joining events. With each cell division, telomeres shorten by approximately 50–200 base pairs due to the "end replication problem" — the inability of DNA polymerase to fully replicate the 3' end of linear DNA. When telomeres shorten beyond a critical threshold, the cell enters replicative senescence or apoptosis — a central mechanism in the Hayflick limit.
Telomerase, the ribonucleoprotein enzyme that extends telomeres by adding TTAGGG repeats, is active in germline cells and certain stem cells, but is largely silenced in somatic cells. Cancer cells typically reactivate telomerase — one reason for their potential for unlimited proliferation. The therapeutic challenge of telomere maintenance research is to extend somatic cell lifespan without inducing oncogenic outcomes. Epithalon's reported activation of telomerase in normal human fibroblasts (without transformation) is the basis of its research interest — though the mechanistic specificity and safety profile require significantly more investigation before any clinical conclusions can be drawn.
It is important to note that while the concept of telomere extension is scientifically compelling, the direct causal link between telomere length and human lifespan is complex and not yet fully established. Long telomeres in isolation are not sufficient to determine biological age or longevity outcome. Epithalon research in this area is preliminary and primarily sourced from in vitro models and small animal studies.
Reconstitution Reference
The following is provided for laboratory reference only. Epithalon is For Research Use Only — not for human administration.
Standard Stock Solution
- Vial size
- 10 mg lyophilised
- Diluent
- Bacteriostatic water (BW)
- Volume added
- 2.0 mL BW
- Stock concentration
- 5,000 mcg/mL (5 mg/mL)
- Storage (reconstituted)
- 2–8°C, up to 28 days
- Storage (lyophilised)
- −20°C, light-protected
In Vitro Working Concentrations
Cell-based assay protocols typically use significantly lower concentrations than the stock. Dilute in PBS or complete cell culture media.
- Typical in vitro range
- 1–100 nM
- Khavinson fibroblast protocol
- 100 nM in DMEM
- Animal model range (research)
- 0.1–1.0 mg/kg/day
- Molecular weight
- 390.35 Da
⚠ Important: Epithalon is not approved for human or veterinary therapeutic use. All use must comply with applicable laboratory research regulations.
Epithalon Pricing Comparison
Epithalon is one of the more accessible longevity research peptides due to its small tetrapeptide structure, enabling cost-effective solid-phase synthesis. Prices vary significantly based on purity certification and documentation quality.
| Supplier | Size | Price | Purity | COA |
| Vendor A (research peptide) | 10 mg | ~$42 | >95% | No |
| Vendor B (specialty peptide) | 10 mg | ~$68 | >98% | Yes |
| Vendor C (longevity compound) | 10 mg | ~$79 | >98% | Yes |
| Rainbow Peptide | 10 mg | $59 | >98% HPLC | Yes — Third-Party |
Pricing surveyed Q1 2026. Given the small molecular weight (390.35 Da), mass spectrometry is the gold standard for confirming product identity. An HPLC purity trace and MS confirmation should both be present in the COA for any Epithalon purchase intended for serious research work.
Frequently Asked Questions
- What is Epithalon?
- Epithalon (AEDG) is a synthetic tetrapeptide developed by Professor Vladimir Khavinson as a synthetic analog of the pineal peptide Epithalamin. It has been studied for over 40 years in relation to telomere biology, melatonin modulation, and cellular ageing research models. For Research Use Only.
- How does Epithalon affect telomeres?
- In vitro research has shown Epithalon activates telomerase in human fibroblast cell lines, maintaining telomere length across more population doublings than untreated controls. This effect has been demonstrated primarily in Khavinson laboratory studies using TRAP assay methodology. Independent replication in Western research centres remains limited.
- What is the molecular weight of Epithalon?
- Epithalon (Ala-Glu-Asp-Gly) has a molecular formula of C14H22N4O9 and a molecular weight of 390.35 Da. Verify this via mass spectrometry when assessing COA quality from any supplier.
- How is Epithalon reconstituted for research?
- A 10 mg vial reconstituted with 2 mL bacteriostatic water yields a 5 mg/mL stock. For cell-based assays, dilute further in PBS to 1–100 nM working concentration. Store reconstituted solution at 2–8°C and use within 28 days.
- Is Epithalon approved for human use?
- No. Epithalon has no regulatory approval from the FDA, EMA, or equivalent authority for human use. All Epithalon supplied by Rainbow Peptide is strictly For Research Use Only — for in vitro and laboratory research only. Not for human consumption.
Order Research-Grade Epithalon
Rainbow Peptide's Epithalon is >98% HPLC-verified with third-party COA, mass spectrometry confirmation, and endotoxin testing included with every order.
- ✓ >98% purity by HPLC
- ✓ Mass spec confirms MW = 390.35 Da
- ✓ Third-party Certificate of Analysis
- ✓ Overnight and 2–3 day delivery available
Published Research References
Studies cited for scientific reference. All data from preclinical or observational models unless stated. Not medical advice.
- Khavinson VK, et al. "Peptide regulation of aging." Bull Exp Biol Med. 2011;151(1):71–74. PubMed 21638889 ↗
- Khavinson VK, Morozov VG. "Peptides of pineal gland and thymus prolong human life." Neuro Endocrinol Lett. 2003;24(3-4):233–240. PubMed 14501180 ↗
- Anisimov VN, et al. "Effect of Epitalon on biomarkers of aging and age-related diseases." Exp Gerontol. 2010;45(7-8):536–543. PubMed 20347968 ↗
- Kossoy G, et al. "Epitalon and colon carcinogenesis." Oncol Rep. 2006;16(5):1115–1119. PubMed 17016612 ↗